Contingent Consideration, Measurement Input

No definition available.

Name:	fold_ContingentConsiderationMeasurementInput
Namespace Prefix:	fold_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	instant

- Definition

Milestone Payable Accrued During Period

+ References

No definition available.

+ Details

Name:	fold_MilestonePayableAccruedDuringPeriod
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow associated with the payment of contingent consideration liabilities.

+ References

No definition available.

+ Details

Name:	fold_PaymentOfContingentConsideration
Namespace Prefix:	fold_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258

+ Details

Name:	us-gaap_AssetsFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- References

No definition available.

+ Details

Name:	us-gaap_AssetsFairValueDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.

+ References

No definition available.

+ Details

Name:	us-gaap_ConvertibleDebtFairValueDisclosures
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.

+ References

No definition available.

+ Details

Name:	us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.

+ References

No definition available.

+ Details

Name:	us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Fair value of financial and nonfinancial obligations.

+ References

+ Details

Name:	us-gaap_LiabilitiesFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- References

No definition available.

+ Details

Name:	us-gaap_LiabilitiesFairValueDisclosureAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=fold_TB200PompeProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MeasurementInputTypeAxis=fold_MeasurementInputProbabilityOfMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Assets and Liabilities Measured at Fair Value (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Assets:
Fair value of assets	$ 427,084	$ 311,700
Liabilities:
Contingent consideration payable	19,700	25,400
Deferred compensation plan liability	2,732	2,258
Fair value of liabilities	22,432	27,658
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of the period	25,400	269,722
Payment of contingent consideration in cash	0	(10,000)	$ (5,000)
Milestone payable, included in accrued expenses	(9,000)	0
Unrealized change in fair value change during the period, included in Statement of Operations	3,300	(234,322)	6,760
Balance, end of the period	19,700	25,400	$ 269,722
Callidus
Liabilities:
Contingent consideration payable	28,700
ATB-200 Pompe Program \| Clinical and Regulatory Approval milestones \| Callidus
Liabilities:
Contingent consideration payable	$ 19,200
ATB-200 Pompe Program \| Minimum \| Clinical and Regulatory Approval milestones \| Callidus \| Probability of Milestone Achievement
Liabilities:
Contingent consideration, measurement input	0.710
ATB-200 Pompe Program \| Maximum \| Clinical and Regulatory Approval milestones \| Callidus \| Probability of Milestone Achievement
Liabilities:
Contingent consideration, measurement input	1
Convertible Notes \| 2016 Convertible Notes
Liabilities:
Fair value of the debt	$ 437,100
Commercial paper
Assets:
Fair value of assets	115,141	79,803
Asset-backed securities
Assets:
Fair value of assets	68,135	30,287
Corporate debt securities
Assets:
Fair value of assets	240,726	199,012
Money market
Assets:
Fair value of assets	3,082	2,598
Level 2
Assets:
Fair value of assets	427,084	311,700
Liabilities:
Contingent consideration payable	0	0
Deferred compensation plan liability	2,732	2,258
Fair value of liabilities	2,732	2,258
Level 2 \| Commercial paper
Assets:
Fair value of assets	115,141	79,803
Level 2 \| Asset-backed securities
Assets:
Fair value of assets	68,135	30,287
Level 2 \| Corporate debt securities
Assets:
Fair value of assets	240,726	199,012
Level 2 \| Money market
Assets:
Fair value of assets	3,082	2,598
Level 3
Liabilities:
Contingent consideration payable	19,700	25,400
Deferred compensation plan liability	0	0
Fair value of liabilities	$ 19,700	$ 25,400
Level 3 \| ATB-200 Pompe Program \| Clinical and Regulatory Approval milestones \| Probability weighted discounted cash flow \| Callidus \| Discount Rate
Liabilities:
Contingent consideration, measurement input	0.10